Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Mid Cap Fund median (34 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 06 Feb 2018 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty Midcap 150 history starts 14 Jan 2019, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Mahindra Manulife Mid Cap Fund |
|---|---|
| 06 Feb 2018 | ₹100.00 |
| 24 Oct 2018 | ₹94.34 |
| 11 Jul 2019 | ₹100.41 |
| 26 Mar 2020 | ₹86.00 |
| 11 Dec 2020 | ₹126.66 |
| 28 Aug 2021 | ₹182.79 |
| 15 May 2022 | ₹178.45 |
| 29 Jan 2023 | ₹198.81 |
| 16 Oct 2023 | ₹270.64 |
| 02 Jul 2024 | ₹392.88 |
| 19 Mar 2025 | ₹361.24 |
| 03 Dec 2025 | ₹407.77 |
| 20 Aug 2026 | ₹457.97 |
| Metric | Mahindra Manulife · Direct NAV ₹42.82 Very High risk ★★★★★ | Category median Mid Cap Fund · 34 funds |
|---|---|---|
| +14.46% | +9.87% | |
| +22.34% | +19.74% | |
| +20.51% | +17.84% | |
| — | +17.01% | |
| +19.52% | +19.29% | |
| +20.48% | — | |
| +25.89% | +20.53% | |
| +25.29% | +19.07% | |
| — | +18.49% | |
| Risk | ||
| 16.92% | 16.20% | |
| 0.94 | 0.83 | |
| 1.26 | 1.14 | |
| -33.10% | -32.95% | |
| Nifty Midcap 150 | — | |
| +3.63% | +2.33% | |
| 0.94 | 0.94 | |
| 102.0% | 98.4% | |
| 85.7% | 87.8% | |
| 0.75% | 0.97% | |
| ₹4,747Cr | ₹7,594Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹1.00K | — | |
| 72% | 40% | |
| Manish Lodha · 5.7y | — | |
| 06 Feb 2018 | — | |
| 58 | — | |
| 26.0% | — | |
| 1.8% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.